Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Completed · Phase 1/Phase 2

Conditions studied: T Cell Lymphoma

In brief

To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.

Key facts

Study ID

NCT03770000

Run by

Rhizen Pharmaceuticals SA

People needed

33

Starts

2019-03-12

Expected to finish

2021-05-14

Last updated by the study team

2022-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically confirmed T-cell lymphomas at the enrolling institution.
• Disease status as defined as relapsed or progressed patients who have received at least one systemic therapy.
• The patients should have received NOT more than three prior systemic combination chemotherapies
• PTCL patients must have measurable disease defined as at least one bidimensional measurable lesion with minimum measurement of > 1.5 cm in the longest diameter.
• Must have ECOG performance status ≤ 2
• Adequate bone marrow, liver and renal function in line with below mentioned laboratory requirements.
• Hemoglobin ≥8.0 g/dL
• Absolute neutrophil count (ANC) ≥1,000/µL
• Platelet count ≥75,000/μL
• Total bilirubin ≤1.5 times the ULN (or ≤3 x ULN, if patient has Gilbert syndrome)
• AST (SGOT) and ALT (SGPT) ≤ 3 x ULN; ≤ 5 ULN in case of liver involvement
• Calculated creatinine clearance (CrCl) > 50 ml/min by Cockcroft-Gault formula
• Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential.
• Provide written informed consent prior to any study-specific screening procedures.
• Willingness and capability to comply with the requirements of the study

You may not qualify if…

• Patient receiving anticancer therapy including any investigational therapy ≤3 weeks or 5 half-lives (whichever is shorter) prior to C1D1.
• Patient who discontinued prior therapy with PI3K inhibitors or HDAC inhibitors due to drug toxicity.
• PTCL patients with Allo-SCT on active GVHD or immunosuppression therapy within 3 months prior to C1D1. CTCL patients with the history of Allo-SCT will be excluded.
• Patient with medical conditions requiring the use of systemic immunosuppressive medications (> 20 mg/day of prednisone or equivalent).
• Severe bacterial, viral or mycotic infection requiring systemic treatment.
• Known seropositive requiring anti-viral therapy for human immunodeficiency virus (HIV) infection.
• Known seropositive requiring anti-viral therapy for hepatitis B virus (HBV) infection OR evidence of active hepatitis B infection as defined by detectable viral load if the antibody tests are positive..
• Known seropositive requiring anti-viral therapy for hepatitis c virus (HCV) infection OR patients with positive hepatitis C virus Ab.
• Subjects with active EBV unrelated to underlying lymphoma (positive serology for anti- EBV VCA IgM antibody and negative for anti-EBV EBNA IgG antibody, or clinical manifestations and positive EBV PCR consistent with active EBV infection.
• Subject with active CMV (positive serology for anti-CMV IgM antibody and negative for anti-CMV IgG antibody and positive CMV PCR with clinical manifestations consistent with active CMV infection) and requiring therapy.
• Uncontrolled or significant cardiovascular disease including, but not limited to:
• Congenital long QT syndrome.
• QTcF interval > 450 msec
• Myocardial infarction or stroke/TIA within the past 6 months
• Uncontrolled angina within the past 3 months
• Significant ECG abnormalities including 2nd degree atrio- ventricular (AV) block (AV) block type II, 3rd degree AV block.
• History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation or torsades de pointes),
• History of other clinically significant heart disease (ie, cardiomyopathy, congestive heart failure with NYHA functional classification III-IV, pericarditis, significant pericardial effusion)
• Requirement for daily supplemental oxygen therapy.

Where it is running

• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• University of California, Hellen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
• University of Colorado Cancer Center — Aurora, Colorado, United States
• University of Miami-Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Rush University Cancer Center — Chicago, Illinois, United States
• The University of Kansas Cancer Center — Fairway, Kansas, United States
• Norton Cancer Institute, St Matthews Campus — Louisville, Kentucky, United States
• University of Michigan — Ann Arbor, Michigan, United States
• John Theurer Cancer Center, Hackensack University Medical Center — Hackensack, New Jersey, United States
• Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
• Cleveland Clinic Taussig Cancer Institute — Cleveland, Ohio, United States
• Oregon Health & Science University — Portland, Oregon, United States
• Vanderbilt Ingram Cancer Center — Nashville, Tennessee, United States
• The University of Texas MD Anderson Cancer Center, — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.